BoE's Ben Broadbent Tells CNBC: Bernanke's QE Remarks Were Not Surprising
Pharmaceuticals Biotechnology and Life Sciences
More
-
Cramer doesn’t ordinarily recommend fresh IPOs immediately in the aftermarket. This one, however, is an exception.
-
NEW YORK-- PDI Inc., which provides sales and marketing services to the biopharmaceutical industry, said Monday that it turned a profit in the first quarter. Net income was $2.1 million, or 14 cents per share. The company had a loss of $272,000, or 2 cents per share, a year ago.
-
*Ranbaxy says money set aside sufficient to cover costs. May 13- Indian generic drugmaker Ranbaxy Laboratories Ltd pleaded guilty on Monday to felony charges related to drug safety and will pay $500 million in civil and criminal fines under the settlement agreement with the U.S. Department of Justice.
-
*Ranbaxy majority-owned by Japan's Daiichi Sankyo. May 13- Indian drugmaker Ranbaxy Laboratories Ltd pleaded guilty on Monday to felony charges related to drug safety and will pay $500 million in civil and criminal fines under the settlement agreement with the U.S. Department of Justice.
-
MOUNTAIN VIEW, Calif.-- Obesity drug maker Vivus Inc. on Monday named two new directors to its board as it finds itself in a proxy fight. CEO of German drugmaker Boehringer Ingelheim from 2003 to 2011, and Plutzky has directed the vascular disease prevention program at Brigham and Women's Hospital in Boston since 1996..
-
NEW YORK-- Shares of Warner Chilcott PLC rose before Monday's opening bell on optimism that it will eventually reach a deal to combine with fellow drugmaker Actavis Inc..
-
DUBLIN, May 13- Irish drugmaker Elan Corporation has agreed a $1 billion royalties deal that could soothe concerns about its potentially risky acquisition strategy and fend off a takeover bid from Royalty Pharma.
-
Elan stepped up its bid to keep its independence on Monday by agreeing a $1 billion deal to buy 21 percent of the royalties that U.S. company Theravance receives from GlaxoSmithKline.
-
Companies like Pfizer Inc and AstraZeneca have grown dependent on higher U.S. prices to generate profits as generic rivals to their best-selling medicines enter the world market, Europe's government-run health plans clamp down on spending and sales growth in emerging markets stutters.
-
District Judge Edward Korman in Brooklyn said he would give the FDA until May 13 to ask a federal appeals court in Manhattan to stay the order, which had been scheduled to take effect on Friday.
-
May 10- The U.S. Food and Drug Administration has approved a new drug to treat chronic obstructive pulmonary disease, a condition often associated with smoking that can include emphysema, chronic bronchitis, or both. The drug, Breo, is an inhaled treatment made by British drugmaker GlaxoSmithKline Plc and Theravance Inc of the United States.
-
VALENCIA, Calif.-- MannKind Corp. said Friday its first-quarter loss widened, as the drug developer spent more on research and development.
-
NEW YORK-- New York City has won nearly $70 million from 44 pharmaceutical companies in a Medicaid fraud lawsuit over the pricing of prescription drugs. The New York City Law Department said Thursday that the city has already been paid about $60 million with the last settlements being processed.
-
Tom Pike, Quintiles CEO, discusses his company's debut on the New York Stock Exchange.
-
May 9- Patent expirations on big-name drugs such as Lipitor and Plavix has resulted in modestly less spending on medicines in the United States for the first time in at least 55 years, according to a report released on Thursday.
-
WASHINGTON, May 8- A U.S. House of Representatives panel advanced a bill on Wednesday on how the federal government should track prescription drugs as they move through the distribution chain, over the objections of some Democrats who said the proposal did not go far enough to ensure safety.
-
After approvals last year from the FDA for 39 novel medicines- a record only beaten in 1996- the healthy pace has continued into 2013.. And drugmakers are getting further help from a new FDA program to accelerate life-saving therapies designated as a "breakthrough," opening to door to earlier approval based on quicker studies, where clinical data is compelling.
-
*FDA sees long-term consequences in recruitment, future leadership. Participants at the Reuters Health Summit in New York this week spoke to the immediate impact of $85 billion in automatic government-wide budget cuts that began on March 1.
-
*Bankers expect steady flow of $1 bln to $5 bln pharma deals. The stock valuations of companies like Regeneron Pharmaceuticals Inc, Gilead Sciences Inc, Celgene Corp and Biogen Idec Inc have skyrocketed in the past year or two alone, making it difficult for large pharmaceutical companies to buy them and leaving a trail of dead deals.
-
May 7- Cubist Pharmaceuticals Inc:. *FDA grants fast track designation for cubist's late-stage antibiotic. *Says expects to initiate a phase 3 vabp program for ceftolozane/tazobactam by.